The Latest Analyst Ratings For Elanco Animal Health
Portfolio Pulse from Benzinga Insights
Elanco Animal Health (NYSE:ELAN) has received mixed analyst ratings over the past quarter, with a recent shift towards more positive evaluations. Analysts from Barclays, Piper Sandler, Goldman Sachs, and Morgan Stanley have adjusted their price targets upwards, reflecting an optimistic outlook on the company's future performance. The average 12-month price target is now $18.2, up 17.42% from the previous $15.50, indicating a bullish sentiment. Despite this, Elanco faces challenges in revenue growth, net margin, ROE, and ROA, lagging behind industry averages.
May 09, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elanco Animal Health has seen a positive shift in analyst ratings with increased price targets, suggesting a bullish outlook despite financial challenges.
The upward revision of price targets by analysts from reputable firms such as Barclays and Goldman Sachs indicates a strong confidence in Elanco's future performance. This optimism is likely to influence investor sentiment positively in the short term, despite the company's challenges in revenue growth, profitability, and asset management. The detailed analysis and adjustments to price targets reflect a comprehensive evaluation of the company's potential, making this news highly relevant and important for investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100